Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.
about
Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adultsNurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fractionAngiotensin-converting enzyme inhibitors for congestive heart failure in childrenAngiotensin-converting enzyme inhibitors for congestive heart failure in childrenNurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents and angiotensin receptor blockers for patients with left ventricular systolic dysfunctionMedical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancerPerioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing surgery-related mortality and morbidityMedical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancerAngiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney diseasePhosphodiesterase III inhibitors for heart failureWhy randomized controlled trials fail but needn't: 2. Failure to employ physiological statistics, or the only formula a clinician-trialist is ever likely to need (or understand!)Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failureAngiotensin receptor blockers in heart failure after the ELITE II trialThe Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trialELITE II and Val-HeFT are different trials: together what do they tell us?A cluster randomized trial to assess the impact of opinion leader endorsed evidence summaries on improving quality of prescribing for patients with chronic cardiovascular disease: rationale and design [ISRCTN26365328]Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy?--A systematic review.Aerobic Exercise and Pharmacological Therapies for Skeletal Myopathy in Heart Failure: Similarities and DifferencesEmerging Novel Therapies for Heart FailureManagement of Patients Admitted with Acute Decompensated Heart FailureRole of estrogen in diastolic dysfunctionMedicaid prescription limits: policy trends and comparative impact on utilization.Heart Failure: a Major Cardiovascular Complication of Diabetes MellitusCardiac remodelling and RAS inhibition2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of theAspirin, ACE inhibitors and arterial stiffnessAspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effectAngiotensin-converting enzyme 2 is an essential regulator of heart functionRevascularization and cardioprotective drug treatment in myocardial infarction patients: how do they impact on patients' survival when delivered as usual careProtecting the heart with cardiac medication in patients with left ventricular dysfunction undergoing major noncardiac vascular surgeryAngiotensin AT(1) receptor signalling modulates reparative angiogenesis induced by limb ischaemiaRole of bradykinin and eNOS in the anti-ischaemic effect of trandolaprilAngiotensin receptor blockers for chronic heart failure and acute myocardial infarctionDifferences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella reviewManagement of end-stage heart failure: a perspective on the Arab Gulf statesSex differences in cardiovascular disease - Impact on care and outcomes.Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.The use of brain natriuretic peptide as a screening test for left ventricular systolic dysfunction- cost-effectiveness in relation to open access echocardiography.Heart failure among Indigenous Australians: a systematic review.Angiotensin-Converting Enzyme Inhibitors and Parameters of Sarcopenia: Relation to Muscle Mass, Strength and Function: Data from the Berlin Aging Study-II (BASE-II).
P2860
Q24186372-D95D75C7-AFAE-402D-A4B0-7A44BFDE42B2Q24187047-2BBD00A2-844A-416C-BDC4-6F1358F6A170Q24188260-D5BE3842-19F7-48BC-A550-B6B2AE6F8A8CQ24202598-97597FE7-D133-40CE-8A9B-95704C118253Q24202952-05A55E9A-F2E9-497E-9A3D-39D9D3C247D1Q24234511-D45FB146-E82D-4751-8020-435308E4C761Q24235838-A0F7584A-F41B-4742-96FF-741426264753Q24241097-4C04E210-CD44-42F0-B21B-1CF11ED6A7A8Q24244197-0765EC03-E7E0-4B4A-AE4A-7E03EAED54C8Q24244978-97A89B65-1FCF-488B-9467-C49F1D951A58Q24554822-4C5CEFE3-B1CC-4459-8F81-47011E7F11F7Q24657798-19BB6B52-E155-411E-99B9-04A91777FE82Q24792591-58477CB7-76EC-42B5-AE72-AD2D405FC8BEQ24793456-217CC394-FA5F-4483-9115-0EA33B389F97Q24806894-31067AFC-35B9-4F2C-B9F4-2166F4560CD6Q24811254-DB143883-C00C-4B6F-9B6E-1359C64E64AAQ24816744-733E82A3-4C97-436A-802D-55AEF5CA1CF2Q26767412-62ECB23F-874C-4278-9292-4A458834DA18Q26778111-4A96E28D-B8B6-41AE-9587-CBE1E7FC13D2Q26786085-CBF9D355-2A45-4FEE-BAFA-B2A1C3193E44Q27026798-438A2DB4-8BF5-415C-A3FE-4DDE0C72ED74Q27306989-EEA6C101-3F79-43FD-A227-3D6B73F06F08Q28066310-D9566B1E-2303-47B3-AAB9-112D623C8A76Q28076749-6EB92E45-289D-4FF4-91B0-13BAA98990ADQ28087002-A2161CD4-9C22-4AA8-867E-C0D9C529EA6EQ28167690-67F0760E-A14E-45CA-A8CC-C21C42E3F175Q28196412-2E857C67-4B6C-45F9-ABEE-B4BAF41BE90AQ28205840-3A0E6708-6E76-4B00-B7CD-FC53F98528B3Q28217493-15397ED3-4CE5-4258-B304-B31B3183B090Q28218068-4075B388-9C15-4668-AE33-918C049A2A97Q28344851-8DEF5BAB-EDAC-442F-9BB9-119CA144B2FFQ28363838-68C7079B-7EF9-4D0D-B51C-0BC00CF07A61Q28366894-3B02223F-EFFF-49C3-A38C-F8140FA8AFF8Q28474985-F79D5440-1FC7-4B9C-B917-5A4E57790DDEQ28751716-3D105C5F-4E5C-4546-9C0B-BCC50152A09DQ30234726-517B4AC3-49CE-4FE6-93AC-6F31E9459DA3Q30248340-CF659385-50B6-4C59-9B08-4297C389CC6AQ30482539-D3027533-E6BB-4847-A923-D21641BD7CF5Q30529760-C1BCC07A-BE99-47F6-B728-F1FF31C98D94Q31132903-F58E2302-6BF6-4C3A-8AF8-681A82F5A4A0
P2860
Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Overview of randomized trials ...... Group on ACE Inhibitor Trials.
@en
type
label
Overview of randomized trials ...... Group on ACE Inhibitor Trials.
@en
prefLabel
Overview of randomized trials ...... Group on ACE Inhibitor Trials.
@en
P1476
Overview of randomized trials ...... Group on ACE Inhibitor Trials.
@en
P304
P356
10.1001/JAMA.1995.03520420066040
P407
P577
1995-05-01T00:00:00Z